P707 Anti-TNFα therapy has no effect on bone mineral density in younger patients with inflammatory bowel disease: A single-centre observational study
Abstract Background Active inflammation negatively affects bone mineral density. Biological treatment, among others silences the excessive reaction of the immune system, which can also reduce the risk of osteoporosis. The aim of the study is to determine whether bone mineral density is higher in pat...
Saved in:
Published in | Journal of Crohn's and colitis Vol. 14; no. Supplement_1; p. S572 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
US
Oxford University Press
15.01.2020
|
Online Access | Get full text |
Cover
Loading…
Summary: | Abstract
Background
Active inflammation negatively affects bone mineral density. Biological treatment, among others silences the excessive reaction of the immune system, which can also reduce the risk of osteoporosis. The aim of the study is to determine whether bone mineral density is higher in patients with biological therapy.
Methods
In total, 112 patients over 18 years of age with CD (Crohn’s Disease) or UC (Ulcerative colitis) were included in the study. The mean value age was 35 years. Patients who had received anti-TNFα therapy (biosimilar infliximab CT-P13 or adalimumab), and who underwent densitometric evaluation after two year treatment, were selected. Those who had never received anti-TNFα therapy were selected as controls. Information regarding age, sex, weight, duration of CD, use of glucocorticoids and bisphosphonates, and signs of disease activity at the time of densitometric measurement were collected. Bone mineral density was measured by dual-energy X-ray absorptiometry (DEXA) within femoral neck and lumbar spine. Results are reported as g/cm2 and presented either as Z-score or as a T-score.
Results
The study group has characterised a mean value BMI (Body Mass Index)—24. The group of patients with anti-TNFαα therapy showed an average T-score left femur −0.7744 (CD) and −0.4382 (UC), but without anti-TNFα therapy −0.6636 (CD) and −0.2208 (UC). The entire study group showed a mean value t-score left femur of −0.54286. There were no significant statistical differences between the examined groups and the effect of anti-TNFα therapy on BMI, T-score left femur, T-score L2–L4
Studied factor
Average
Median
Standard deviation
Lower quartile
Upper quartile
Statistical analysis
Crohn’s disease (CD)
Anti-TNFα therapy
BMI
23.1372
21.7000
3.67281
20.1000
26.6000
p > 0.05
L2–L4 T-score
−0.4953
−0.6000
1.36468
−1.5000
0.7000
Left femur T-score
−0.7744
−0.8000
1.03420
−1.8000
−0.1000
No anti-TNFα therapy
BMI
23.6545
24.0000
3.56549
20.5000
26.6000
p > 0.05
L2–L4 T -score
−0.3273
−0.6000
1.33423
−1.1000
0.8000
Left femur T-score
−0.6636
−0.8000
0.79909
−1.1000
−0.3000
Colitis ulcerosa (UC)
Anti-TNFα therapy
BMI
26.0206
23.9500
11.27138
20.5000
28.2000
p > 0.05
L2-L4 T -score
−0.1529
−0.2000
1.30853
−1.0000
0.7000
Left femur T - score
−0.4382
−0.4000
1.06002
−1.2000
0.0000
No anti-TNFα therapy
BMI
23.8833
22.7500
4.83912
20.5000
27.9000
p > 0.05
L2-L4 T-score
0.0833
0.0000
1.27541
−0.6500
1.0500
Left femur T-score
−0.2208
−0.2500
0.83613
−0.8000
0.2000
Conclusion
The results of the preliminary study assessing the effect of anti-TNFα therapy on bone mineral density among the two treatment groups (CD and UC) do not indicate significant differences after the introduction of such therapy |
---|---|
ISSN: | 1873-9946 1876-4479 |
DOI: | 10.1093/ecco-jcc/jjz203.835 |